Key Points
- Michael Feld, BDX Executive VP, sold 74 shares on April 27 at an average price of $151.94 for $11,243.56, reducing his stake by 0.35% to 21,159 shares; the sale was executed under a pre-arranged Rule 10b5-1 trading plan and disclosed to the SEC.
- BDX reported quarterly EPS of $2.91 (beat by $0.10) but revenue of $4.49B missed estimates; management set FY2026 guidance of 12.35–12.65 EPS, declared a $1.05 quarterly dividend (2.8% yield), and approved a $10M share buyback program.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 74 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $151.94, for a total transaction of $11,243.56. Following the transaction, the executive vice president owned 21,159 shares in the company, valued at approximately $3,214,898.46. This trade represents a 0.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Feld also recently made the following trade(s):
- On Thursday, February 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $181.84, for a total transaction of $13,638.00.
Becton, Dickinson and Company Stock Performance
Shares of BDX opened at $149.38 on Wednesday. The company's fifty day moving average is $162.11 and its 200-day moving average is $182.48. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The firm has a market cap of $42.53 billion, a price-to-earnings ratio of 24.37, a price-to-earnings-growth ratio of 10.68 and a beta of 0.29. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company had revenue of $4.49 billion for the quarter, compared to analyst estimates of $5.15 billion. During the same quarter in the prior year, the business posted $3.43 EPS. Becton, Dickinson and Company's quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.56 EPS for the current fiscal year.
Becton, Dickinson and Company declared that its Board of Directors has approved a stock buyback program on Tuesday, January 27th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's leadership believes its stock is undervalued.
Becton, Dickinson and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.8%. Becton, Dickinson and Company's dividend payout ratio is 68.52%.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on BDX shares. Zacks Research upgraded shares of Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a research note on Friday, April 10th. Barclays began coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an "overweight" rating and a $202.00 target price for the company. Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Argus cut their target price on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating for the company in a research report on Monday, March 23rd. Finally, Wells Fargo & Company cut their target price on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an "equal weight" rating for the company in a research report on Tuesday, February 10th. Six equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and an average price target of $189.08.
Check Out Our Latest Analysis on Becton, Dickinson and Company
Institutional Trading of Becton, Dickinson and Company
A number of hedge funds have recently bought and sold shares of BDX. SOA Wealth Advisors LLC. increased its holdings in shares of Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 95 shares during the period. Activest Wealth Management raised its position in shares of Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 97 shares during the last quarter. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the third quarter valued at about $25,000. Steph & Co. raised its position in shares of Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier's stock valued at $26,000 after buying an additional 65 shares during the last quarter. Finally, SHP Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at about $26,000. 86.97% of the stock is owned by institutional investors.
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
